Astellas Pharma Inc.: U.S. FDA Approves Expanded Label for Astellas' IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy
IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...
NHS warns of animal-related symptom in eyes that need urgent medical attention
According to the NHS website, while floaters - such as dots and lines - or flashes of light in your vision are typically ...
ScienceAlert5d
Can a Supplement Really Help You Control Your Pesky Eye Floaters?
If you look up at the sky on a clear day, you might notice little cobweb-like structures drifting across your field of vision ...
Medscape4d
FDA Approves Mirdametinib for Neurofibromatosis Type 1
The kinase inhibitor is now approved for adults and children aged ≥ 2 years with neurofibromatosis type 1 who have ...
Mid Day5dOpinion
The surgical duality
A late night, another patient in distress or a tiff with the spouse—patients will never know the worries that weigh on their ...
New vaccine keeps advanced kidney cancer from recurring: Here's all you need to know
The new vaccine is "personalized," meaning it is designed to train the patient's immune system to recognize and eliminate any remaining cells of that person's cancer.
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLIâ„¢ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...